Harmony Biosciences Holdings (HRMY) Long-Term Deferred Tax (2022 - 2026)

Harmony Biosciences Holdings has reported Long-Term Deferred Tax for 5 years, with the latest figure at $153.6 million in Q1 2026.

• Quarterly Long-Term Deferred Tax fell 21.13% year-over-year to $153.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.6 million (down 21.13% YoY) and the FY2025 annual result came in at $149.7 million, down 21.38% from the prior year.
• Long-Term Deferred Tax grew to $153.6 million in Q1 2026 per HRMY's latest filing, from $149.7 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $201.2 million in Q2 2025 and troughed at $81.7 million in Q3 2022.
• A 5-year average of $143.6 million and a median of $149.7 million in 2025 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax surged 92.55% in 2024, then slipped 21.38% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $85.9 million in 2022, then jumped by 67.74% to $144.2 million in 2023, then jumped by 32.07% to $190.4 million in 2024, then retreated by 21.38% to $149.7 million in 2025, then climbed by 2.58% to $153.6 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $153.6 million, $149.7 million, and $157.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.